Pacira BioSciences Inc (NASDAQ: PCRX) is 38.16% higher on its value in year-to-date trading and has touched a low of $11.16 and a high of $34.01 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PCRX stock was last observed hovering at around $25.75 in the last trading session, with the day’s gains setting it 0.28%.
Currently trading at $26.03, the stock is 21.18% and 32.59% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.98 million and changing 1.09% at the moment leaves the stock 25.53% off its SMA200. PCRX registered -18.78% loss for a year compared to 6-month loss of 27.88%. The firm has a 50-day simple moving average (SMA 50) of $19.6316 and a 200-day simple moving average (SMA200) of $20.73665.
The stock witnessed a 31.40% gain in the last 1 month and extending the period to 3 months gives it a 54.66%, and is 15.95% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.75% over the week and 5.87% over the month.
Pacira BioSciences Inc (PCRX) has around 712 employees, a market worth around $1.20B and $694.96M in sales. Fwd P/E is 7.91. Profit margin for the company is -13.06%. Distance from 52-week low is 133.16% and -23.46% from its 52-week high. The company has generated returns on investments over the last 12 months (-7.67%).
with sales reaching $184.2M over the same period.The EPS is expected to grow by 11.36% this year, but quarterly earnings will post 3.65% year-over-year. Quarterly sales are estimated to grow 1.63% in year-over-year returns.
318.0 institutions hold shares in Pacira BioSciences Inc (PCRX), with institutional investors hold 116.35% of the company’s shares. The shares outstanding are 46.15M, and float is at 44.70M with Short Float at 12.18%. Institutions hold 113.85% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 8.01 million shares valued at $229.08 million. The investor’s holdings represent 17.3406 of the PCRX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 5.08 million shares valued at $145.48 million to account for 11.0123 of the shares outstanding. The other top investors are PACER ADVISORS, INC. which holds 2.16 million shares representing 4.684 and valued at over $61.88 million, while RENAISSANCE TECHNOLOGIES LLC holds 4.4748 of the shares totaling 2.07 million with a market value of $59.11 million.
Pacira BioSciences Inc (PCRX) Insider Activity
The most recent transaction is an insider sale by SLONIN JONATHAN, the company’s Chief Medical Officer. SEC filings show that SLONIN JONATHAN sold 879 shares of the company’s common stock on Jan 06 ’25 at a price of $18.40 per share for a total of $16174.0. Following the sale, the insider now owns 93444.0 shares.
Still, SEC filings show that on Dec 13 ’24, GAUGLER DARYL (Chief Operating Officer) disposed off 500 shares at an average price of $19.76 for $9880.0. The insider now directly holds 115,200 shares of Pacira BioSciences Inc (PCRX).
